Outpatient psychotherapy is a $50Bn global market and $25Bn+ is spent on outpatient mental therapy every year in the US. Despite a widespread, growing, and acute need for therapy solutions, there isn’t a single one that is accessible in a timely way, affordable, and effective in driving clinical outcomes. Users need to wait for weeks to get in touch with a therapist who may or may not be the right fit for them. This significantly delays the process of seeking help and worsens the symptoms for many users.
z21 Ventures is pleased to announce our strategic investment in Meomind. By uniquely creating a vast library of pre-recorded therapy sessions, Meomind is on the path to providing on-demand access to high-quality relatable solutions to millions of users. With 70k+ members on the platform, 80% of members have reported feeling better in 2.5 weeks. This makes Meomind a great benefit that employers and health plans can offer to support the mental well-being of members.
This partnership is a testament to our belief in the role of technology to make effective mental well-being solutions accessible to all. Meomind partners with world-class therapists to curate therapy sessions relatable to diverse scenarios.
“The entire z21 team has been incredibly helpful in connecting us to a rich network of GTM experts, technologists, and investors. z21 has built a unique value proposition with the vast reach of its LPs who not only have deep expertise but are also very generous with their time and advice.” – Sushant Gupta, CEO, Meomind
We look forward to working closely with Sushant and the Meomind team to disrupt the mental health landscape.